AI Prova (CEO Pyo Se-min), a company specializing in artificial intelligence (AI) for gastrointestinal endoscopy, announced on the 11th that it was selected as a "Seoul AI Hub Membership Company"—a program operated by the Seoul Metropolitan Government to support promising AI firms in research and development, commercialization, and global expansion.
Following this selection, AI Prova plans to accelerate the supply of its "ScopeEndo" solution to domestic medical institutions and expand into overseas markets. ScopeEndo is an ultra-lightweight AI solution for endoscopy that has received Class II digital medical device certification from the Ministry of Food and Drug Safety.
AI Prova CI / IT Chosun DB
During gastric and colonoscopies, ScopeEndo uses AI to analyze video feeds in real time, detecting abnormalities such as polyps and estimating the size of lesions in millimeters (mm). It also provides quality control features, such as verifying the areas examined during a gastroscopy and measuring the withdrawal time during a colonoscopy. According to the company, evaluations by external accredited organizations showed a detection performance (based on F1 score) of over 91% for gastroscopies and over 93% for colonoscopies.
Another key feature is its ultra-lightweight design. Through proprietary AI model optimization, the company has reduced computational requirements by approximately 94% compared to standard models, allowing the software to run on a compact mini PC rather than requiring large-scale graphics processing unit (GPU) hardware. The system can be mounted on the back of existing endoscopy monitors, and the company notes that this reduces hardware implementation costs by more than 30%. ‘ScopeEndo,’ an Ultra-Lightweight Endoscopic AI Solution by AIProba / AIProba
AIProba is currently conducting clinical validation through a network of university hospitals, including Hallym University Medical Center. The company aims to obtain ISO 13485 (Medical Devices – Quality Management Systems) certification by the first half of 2027 and plans to expand into Southeast Asian markets, including Vietnam, Indonesia, and Malaysia.
Pyo Se-min, CEO of AIProba, stated, “Following our Class II digital medical device certification from the Ministry of Food and Drug Safety, our selection as a member company of the Seoul AI Hub serves as both internal and external recognition of our ultra-lightweight medical AI technology—a solution designed to overcome the barriers posed by high-cost hardware and enhance the precision of gastrointestinal endoscopic diagnostics.” He added, “By actively leveraging the infrastructure and network of the Seoul AI Hub, we intend to rapidly deploy ‘ScopeEndo’ across domestic medical settings. Our goal is to evolve into a global medical AI company that ensures high-quality endoscopic examinations are accessible everywhere—from large-scale hospitals to local clinics—thereby bridging the gap in medical care.”
Reporter Jung Jong-gil
Source: IT Chosun (https://it.chosun.com)
